Fidaxomicin to Prevent Clostridium Difficile Colonization
NCT01552668 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL
Last updated 2014-05-28
Summary
The purpose of this research study is to evaluate the effectiveness of an antibiotic called fidaxomicin in preventing C. difficile infection.
Conditions
- Clostridium Difficile Infection
Interventions
- DRUG
-
Fidaxomicin
Receive 200 mg of fidaxomicin twice daily
- DRUG
-
Receive Placebo twice daily
Sponsors & Collaborators
-
Centers for Disease Control and Prevention
collaborator FED -
Washington University School of Medicine
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-09-30
- Primary Completion
- 2013-12-31
- Completion
- 2013-12-31
Countries
- United States
Study Locations
More Related Trials
-
Impact of Oral Antibiotic Treatment on C. Difficile
NCT02057198 ·Status: COMPLETED ·Phase: PHASE4
-
Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin
NCT05201079 ·Status: COMPLETED ·Phase: PHASE3
-
A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System
NCT01775397 ·Status: TERMINATED ·Phase: PHASE4
-
Optimal Treatment for Recurrent Clostridium Difficile
NCT02667418 ·Status: TERMINATED ·Phase: PHASE4
-
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)
NCT01691248 ·Status: COMPLETED ·Phase: PHASE3
-
Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea
NCT01670149 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)
NCT02784002 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
NCT01259726 ·Status: COMPLETED ·Phase: PHASE2
-
Fecal Microbiota Transplantation in Clostridioides Difficile Infection First Episode and First Recurrence
NCT05266807 ·Status: RECRUITING ·Phase: PHASE3
-
Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury
NCT02355938 ·Status: TERMINATED ·Phase: PHASE4
-
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
NCT01591863 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population
NCT02254967 ·Status: COMPLETED ·Phase: PHASE4
-
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
NCT07221708 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients
NCT02214771 ·Status: COMPLETED
-
STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection
NCT07120490 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy of Rifaximin in Preventing Campylobacteriosis
NCT02280044 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease
NCT06794944 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection
NCT02464306 ·Status: WITHDRAWN ·Phase: PHASE4
-
Vancomycin Taper to Prevent Recurrent Clostridioides Difficile
NCT07328971 ·Status: RECRUITING ·Phase: PHASE3
-
Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection
NCT03760484 ·Status: TERMINATED ·Phase: PHASE2
-
Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)
NCT00314951 ·Status: COMPLETED ·Phase: PHASE3
-
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
NCT00304356 ·Status: COMPLETED ·Phase: PHASE3
-
TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
NCT03388268 ·Status: COMPLETED ·Phase: PHASE4
-
Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection
NCT02237859 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
NCT03462459 ·Status: COMPLETED ·Phase: PHASE2